Its signaling abnormalities have a prominent role in the pathogenesis of GBM; approximately 50% of GBM patients have tumors harboring EGFR amplification on chromosome 7 and half of these cases have the exon 2–7 deletion, known as EGFR variant III (EGFRvIII) [9]. The gene discussed is EGFR; the disease is glioblastoma.